Clinical Trial Update: ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating fulvestrant (ICI 182780) in women with Stage I or Stage II primary breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (ICI 182780) (fulvestrant)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED